Discover the best biotech ETFs to diversify your portfolio, gain exposure to cutting-edge biotech innovations, and reduce risk in a volatile sector.

VHT offers broad diversification across 429 healthcare holdings, while PPH concentrates on 26 drugmakers for higher growth ...

From broad domestic exposure to global pharma and biotech, these funds cover the healthcare sector's main themes.

PJP delivers lower volatility and higher income with concentrated pharma exposure, while XBI offers broader biotech growth at ...

Broader diversification and lower volatility set these healthcare ETFs apart, with each fund targeting a distinct segment of the industry.

FHLC is the far cheaper option for long-term investors, charging an expense ratio of just 0.08% compared to BBH's 0.35%. FHLC also pays a higher trailing dividend yield of 1.40%, nearly 0.9 percentage ...

The Invesco Pharmaceuticals ETF (PJP) was launched on 06/23/2005, and is a smart beta exchange traded fund designed to offer broad exposure to the Health Care ETFs category of the market. For a long ...

Biotech is having a moment, and the numbers are hard to ignore. The SPDR S&P Biotech ETF (NYSEARCA:XBI) climbed 17.27% over ...

Pharmaceutical shares just witnessed their strongest week in 23 years, thanks to Pfizer's PFE major drug-pricing and tariff deal with the U.S. government that helped ease long-standing pressures on ...

Diversify Outside the U.S. Heavyweights: Global healthcare ETFs like iShares Global Healthcare ETF (NYSE: MIXJ) provide exposure to pharma names outside the U.S., reducing risk from domestic tariff ...